Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells

Molecular Cancer

Volumn 8, Issue , 2009, Pages 80-

  Michaelis, Martin ^a   Klassert, Denise ^a   Barth, Susanne ^b   Suhan, Tatyana ^a   Breitling, Rainer ^c   Mayer, Bernd ^d   Hinsch, Nora ^a   Doerr, Hans W ^a   Cinatl, Jaroslav ^a   Cinatl jr, Jindrich ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Blue drugs GmbH   (Germany)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d Emergentec Biodevelopment GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; DOXORUBICIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GELATINASE A; GELATINASE B; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; OSTEONECTIN; PIGMENT EPITHELIUM DERIVED FACTOR; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; SINGLE DRUG DOSE; TRANSCRIPTOMICS; TUMOR VASCULARIZATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; CULTURE MEDIA, CONDITIONED; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED STRAINS; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 70449360912     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-80     Document Type: Article

References (71)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007, 369:2106-2120. 10.1016/S0140-6736(07)60983-0, 17586306.
2. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999, 17:2264-2279.
3. Goldsmith KC, Hogarty MD. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett 2005, 228:133-141. 10.1016/j.canlet.2005.01.048, 15927359.
4. Shah AN, Gallick GE. Src, chemoresistance and epithelial to mesenchymal transition: are they related?. Anticancer Drugs 2007, 18:371-375. 10.1097/CAD.0b013e32801265d7, 17351389.
5. Ogbomo H, Michaelis M, Klassert D, Doerr HW, Cinatl J. Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells. Neoplasia 2008, 10:1402-1410. 2586691, 19048119.
6. Liu F, Chen Z, Wang J, Shao X, Cui Z, Yang C, Zhu Z, Xiong D. Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. Neoplasia 2008, 10:1275-1284. 2570604, 18953437.
7. Blaheta RA, Daher FH, Michaelis M, Hasenberg C, Weich EM, Jonas D, Kotchetkov R, Doerr HW, Cinatl J. Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression. BMC Cancer 2006, 6:294. 10.1186/1471-2407-6-294, 1780063, 17181871.
8. Blaheta RA, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B, Jonas D, Doerr HW, Cinatl J. Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer 2007, 96:1699-1706. 10.1038/sj.bjc.6603777, 2359931, 17505515.
9. Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, Cinatl J, Doerr HW, Cinatl J. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol 2006, 28:439-446.
10. Müller M, Schleithoff ES, Stremmel W, Melino G, Krammer PH, Schilling T. One, two, three--p53, p63, p73 and chemosensitivity. Drug Resist Updat 2006, 9:288-306. 10.1016/j.drup.2007.01.001, 17287142.
11. Fernandez-Luna JL. Regulation of pro-apoptotic BH3-only proteins and its contribution to cancer progression and chemoresistance. Cell Signal 2008, 20:1921-1926. 10.1016/j.cellsig.2008.04.015, 18555662.
12. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193. 10.1093/bioinformatics/19.2.185, 12538238.
13. Mi H, Guo N, Kejariwal A, Thomas PD. PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res 2007, (35 Database):D247-52. 10.1093/nar/gkl869, 1716723, 17130144.
14. Cho RJ, Campbell MJ. Transcription, genomes, function. Trends Genet 2000, 16:409-415. 10.1016/S0168-9525(00)02065-5, 10973070.
15. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995, 57:289-300.
16. Cinatl J, Vogel JU, Cinatl J, Weber B, Rabenau H, Novak M, Kornhuber B, Doerr HW. Long-term productive human cytomegalovirus infection of a human neuroblastoma cell line. Int J Cancer 1996, 65:90-96. 10.1002/(SICI)1097-0215(19960103)65:1<90::AID-IJC16>3.0.CO;2-M, 8543403.
17. Kotchetkov R, Cinatl J, Blaheta R, Vogel JU, Karaskova J, Squire J, Hernáiz Driever P, Klingebiel T, Cinatl J. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer 2003, 104:36-43. 10.1002/ijc.10917, 12532417.
18. Kotchetkov R, Driever PH, Cinatl J, Michaelis M, Karaskova J, Blaheta R, Squire JA, Von Deimling A, Moog J, Cinatl J. Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol 2005, 27:1029-1037.
19. Michaelis M, Cinatl J, Anand P, Rothweiler F, Kotchetkov R, von Deimling A, Doerr HW, Shogen K, Cinatl J. Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. Cancer Lett 2007, 250:107-116. 10.1016/j.canlet.2006.09.018, 17084521.
20. Michaelis M, Bliss J, Arnold SC, Hinsch N, Rothweiler F, Deubzer HE, Witt O, Langer K, Doerr HW, Wels WS, Cinatl J. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins. Clin Cancer Res 2008, 14:6531-6537. 10.1158/1078-0432.CCR-08-0821, 18927293.
21. Cinatl J, Michaelis M, Driever PH, Cinatl J, Hrabeta J, Suhan T, Doerr HW, Vogel JU. Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. Neoplasia 2004, 6:725-735. 10.1593/neo.04265, 1531676, 15720798.
22. Cinatl J, Margraf S, Vogel JU, Scholz M, Cinatl J, Doerr HW. Human cytomegalovirus circumvents NF-kappa B dependence in retinal pigment epithelial cells. J Immunol 2001, 167:1900-1908.
23. Papoutsi M, Sleeman JP, Wilting J. Interaction of rat tumor cells with blood vessels and lymphatics of the avian chorioallantoic membrane. Microsc Res Tech 2001, 55:100-107. 10.1002/jemt.1161, 11596155.
24. Schadendorf D, Kern MA, Artuc M, Pahl HL, Rosenbach T, Fichtner I, Nürnberg W, Stüting S, von Stebut E, Worm M, Makki A, Jurgovsky K, Kolde G, Henz BM. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol 1996, 135:1889-1898. 10.1083/jcb.135.6.1889, 2133968, 8991099.
25. Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T, Bibby M. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 2004, 40:298-307. 10.1016/j.ejca.2003.10.011, 14728946.
26. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998, 273:13313-13316. 10.1074/jbc.273.21.13313, 9582377.
27. Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, Law PY, Hebbel RP. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 1999, 247:495-504. 10.1006/excr.1998.4359, 10066377.
28. Michaelis M, Suhan T, Michaelis UR, Beek K, Rothweiler F, Tausch L, Werz O, Eikel D, Zörnig M, Nau H, Fleming I, Doerr HW, Cinatl J. Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells. Cell Death Differ 2006, 13:446-453. 10.1038/sj.cdd.4401759, 16167071.
29. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 2003, 31:1171-1177. 10.1042/BST0311171, 14641020.
30. Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 2007, 13:2825-2830. 10.1158/1078-0432.CCR-06-2416, 17504979.
31. Jiang BH, Liu LZ. AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets 2008, 8:19-26. 10.2174/156800908783497122, 18288940.
32. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000, 6:1900-1908.
33. Rössler J, Taylor M, Geoerger B, Farace F, Lagodny J, Peschka-Süss R, Niemeyer CM, Vassal G. Angiogenesis as a target in neuroblastoma. Eur J Cancer 2008, 44:1645-1656. 10.1016/j.ejca.2008.05.015, 18614349.
34. Tsuchida R, Das B, Yeger H, Koren G, Shibuya M, Thorner PS, Baruchel S, Malkin D. Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. Oncogene 2008, 27:3923-3934. 10.1038/onc.2008.38, 18332870.
35. Hatzi E, Murphy C, Zoephel A, Rasmussen H, Morbidelli L, Ahorn H, Kunisada K, Tontsch U, Klenk M, Yamauchi-Takihara K, Ziche M, Rofstad EK, Schweigerer L, Fotsis T. N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. Oncogene 2002, 21:3552-3561. 10.1038/sj.onc.1205440, 12032857.
36. Schramm A, von Schuetz V, Christiansen H, Havers W, Papoutsi M, Wilting J, Schweigerer L. High activin A-expression in human neuroblastoma: suppression of malignant potential and correlation with favourable clinical outcome. Oncogene 2005, 24:680-687. 10.1038/sj.onc.1208087, 15580313.
37. Kang J, Rychahou PG, Ishola TA, Mourot JM, Evers BM, Chung DH. N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene 2008, 27:3999-4007. 10.1038/onc.2008.15, 2614290, 18278068.
38. Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med 2007, 85:1175-1186. 10.1007/s00109-007-0221-2, 17589818.
39. Amoh Y, Li L, Yang M, Jiang P, Moossa AR, Katsuoka K, Hoffman RM. Hair follicle-derived blood vessels vascularize tumors in skin and are inhibited by doxorubicin. Cancer Res 2005, 65:2337-2343. 10.1158/0008-5472.CAN-04-3857, 15781648.
40. Amoh Y, Li L, Katsuoka K, Hoffman RM. Chemotherapy targets the hair-follicle vascular network but not the stem cells. J Invest Dermatol 2007, 127:11-15. 10.1038/sj.jid.5700486, 16841031.
41. Gustafson DL, Rastatter JC, Colombo T, Long ME. Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci 2002, 91:1488-1501. 10.1002/jps.10161, 12115848.
42. Gustafson DL, Merz AL, Long ME. Pharmacokinetics of combined doxorubicin and paclitaxel in mice. Cancer Lett 2005, 220:161-169. 10.1016/j.canlet.2004.09.007, 15766591.
43. Breistøl K, Hendriks HR, Fodstad O. Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug. Eur J Cancer 1999, 35:1143-1149. 10.1016/S0959-8049(99)00074-X, 10533461.
44. Lev DC, Onn A, Melinkova VO, Miller C, Stone V, Ruiz M, McGary EC, Ananthaswamy HN, Price JE, Bar-Eli M. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 2004, 22:2092-2100. 10.1200/JCO.2004.11.070, 15123733.
45. Kato Y, Okollie B, Raman V, Vesuna F, Zhao M, Baker SD, Bhujwalla ZM, Artemov D. Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biol Ther 2007, 6:891-897. 10.1158/1535-7163.MCT-06-0125, 2094098, 17582214.
46. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE 2008, 3:e3077. 10.1371/journal.pone.0003077, 2518121, 18728788.
47. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008, 14:5000-5005. 10.1158/1078-0432.CCR-08-0746, 18698017.
48. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001, 91:2026-2032. 10.1002/1097-0142(20010601)91:11<2026::AID-CNCR1228>3.0.CO;2-E, 11391581.
49. Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT, Zou B, Zhu YB, Jiang SH, Wong WM, Chan AO, Yuen MF, Lam SK, Kung HF, Wong BC. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 2003, 63:7724-7732.
50. Tu SP, Cui JT, Liston P, Huajiang X, Xu R, Lin MC, Zhu YB, Zou B, Ng SS, Jiang SH, Xia HH, Wong WM, Chan AO, Yuen MF, Lam SK, Kung HF, Wong BC. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology 2005, 128:361-375. 10.1053/j.gastro.2004.11.058, 15685548.
51. Zhao Y, Shen S, Guo J, Chen H, Greenblatt DY, Kleeff J, Liao Q, Chen G, Friess H, Leung PS. Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J Surg Res 2006, 136:325-335. 10.1016/j.jss.2006.06.031, 17054996.
52. Mirmohammadsadegh A, Mota R, Gustrau A, Hassan M, Nambiar S, Marini A, Bojar H, Tannapfel A, Hengge UR. ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol 2007, 127:2207-2215. 10.1038/sj.jid.5700870, 17508026.
53. Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, Chang CJ, Yang Y, Lai CC, Lee DF, Yen CJ, Chen YJ, Hsu JM, Kuo HP, Lin CY, Tsai FJ, Li LY, Tsai CH, Hung MC. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res 2008, 68:6109-6117. 10.1158/0008-5472.CAN-08-0579, 2676572, 18676833.
54. Carroll VA, Ashcroft M. Regulation of angiogenic factors by HDM2 in renal cell carcinoma. Cancer Res 2008, 68:545-552. 10.1158/0008-5472.CAN-06-4738, 18199551.
55. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002, 5:234-248. 10.1016/S1368-7646(02)00120-6, 12531180.
56. Caporali S, Levati L, Starace G, Ragone G, Bonmassar E, Alvino E, D'Atri S. AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol Pharmacol 2008, 74:173-183. 10.1124/mol.107.044743, 18413665.
57. Gagnon V, Van Themsche C, Turner S, Leblanc V, Asselin E. Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 2008, 13:259-271. 10.1007/s10495-007-0165-6, 18071906.
58. Mitsiades CS, Mitsiades N, Koutsilieris M. The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 2004, 4:235-256. 10.2174/1568009043333032, 15134532.
59. Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, Le XF. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006, 25:6986-6996. 10.1038/sj.onc.1209685, 16715132.
60. Xia C, Meng Q, Cao Z, Shi X, Jiang BH. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. J Cell Physiol 2006, 209:56-66. 10.1002/jcp.20707, 16775835.
61. Anfosso L, Efferth T, Albini A, Pfeffer U. Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J 2006, 6:269-278.
62. Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, Lokshin A, Gorelik E. Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 2008, 123:2031-2040. 10.1002/ijc.23732, 18697197.
63. Zaghloul N, Hernandez SL, Bae JO, Huang J, Fisher JC, Lee A, Kadenhe-Chiweshe A, Kandel JJ, Yamashiro DJ. Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. Int J Oncol 2009, 34:401-407.
64. Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, Yoon SS. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 2008, 14:1529-1539. 10.1158/1078-0432.CCR-07-4126, 18316578.
65. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676. 10.1056/NEJMoa072113, 18160686.
66. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996, 14:405-414.
67. Ribatti D, Surico G, Vacca A, De Leonardis F, Lastilla G, Montaldo PG, Rigillo N, Ponzoni M. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci 2001, 68:1161-1168. 10.1016/S0024-3205(00)01030-4, 11228100.
68. Katzenstein HM, Cohn SL, Crawford S, Meitar D. Angiogenesis in neuroblastoma. J Clin Oncol 2000, 18:2789-2791.
69. Cañete A, Navarro S, Bermúdez J, Pellín A, Castel V, Llombart-Bosch A. Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients. J Clin Oncol 2000, 18:27-34.
70. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, König R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006, 24:5070-5078. 10.1200/JCO.2006.06.1879, 17075126.
71. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, Seeger RC. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006, 98:1193-1203.